Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial

NCT00164892 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

214

Enrollment

OTHER

Sponsor class

Conditions

Cancer of Stomach

Interventions

DRUG: Oral Vioxx (Rofecoxib)

Sponsor

Chinese University of Hong Kong